Stoke Therapeutics (NASDAQ:STOK) Shares Break Below 50-Day Moving Average – Should You Sell?

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s stock price crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $26.52 and traded as low as $26.14. Stoke Therapeutics shares last traded at $26.20, with a volume of 501,151 shares trading hands.

Analyst Ratings Changes

STOK has been the subject of several recent research reports. JPMorgan Chase & Co. began coverage on shares of Stoke Therapeutics in a research note on Friday, August 21st. They set an “overweight” rating and a $40.00 target price for the company. Weiss Ratings cut Stoke Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Chardan Capital restated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Guggenheim reaffirmed a “buy” rating and set a $60.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Finally, Canaccord Genuity Group decreased their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research report on Tuesday, August 4th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Stoke Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $44.17.

Stoke Therapeutics Stock Performance

The stock’s 50-day moving average price is $26.52 and its 200-day moving average price is $30.77. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of -6.95 and a beta of 1.36.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Thursday, October 29th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.15). Stoke Therapeutics had a negative return on equity of 67.30% and a negative net margin of 862.07%. The firm had revenue of $11.26 million during the quarter, compared to analyst estimates of $8.21 million. Analysts anticipate that Stoke Therapeutics, Inc. will post -3.91 earnings per share for the current year.

Insiders Place Their Bets

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 2,861 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $91,637.83. Following the sale, the general counsel owned 21,225 shares of the company’s stock, valued at approximately $679,836.75. This represents a 11.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Edward M. Md Kaye sold 12,567 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $402,521.01. Following the completion of the transaction, the director owned 124,557 shares of the company’s stock, valued at approximately $3,989,560.71. This represents a 9.16% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 27,418 shares of company stock worth $860,914. 9.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in STOK. Quantbot Technologies LP purchased a new stake in shares of Stoke Therapeutics in the 2nd quarter worth about $34,000. KBC Group NV purchased a new position in Stoke Therapeutics during the 1st quarter valued at about $36,000. Western Wealth Management LLC purchased a new position in Stoke Therapeutics during the 1st quarter valued at about $55,000. Sterling Capital Management LLC increased its holdings in Stoke Therapeutics by 849.7% during the 3rd quarter. Sterling Capital Management LLC now owns 1,833 shares of the company’s stock valued at $48,000 after acquiring an additional 1,640 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in Stoke Therapeutics by 195.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company’s stock worth $60,000 after acquiring an additional 1,215 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders. Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.